A Bayesian path analysis to estimate causal effects of bazedoxifene acetate on incidence of vertebral fractures,either directly or through non-linear changes in bone mass density

Abstract

Background/Aims

Bone mass density values have been related with risk of vertebral fractures in post-menopausal women. However, bone mass density is not perfectly accurate in predicting risk of fracture, which decreases its usefulness as a surrogate in clinical trials. We propose a modeling framework with three interconnected parts to improve the evaluation of bone mass density accuracy in forecasting fractures after treatment.

Methods

The modeling framework includes: (1) a piecewise regression to describe non-linear temporal BMD changes more accurately than crude percent changes, (2) a structural equation model to analyze interdependencies among vertebral fractures and their potential risk factors in preference to regression techniques that consider only directional associations, and (3) a counterfactual causal interpretation of the direct and indirect relationships between treatment and occurrence of vertebral fractures. We apply the methods to BMD repeated measurements from a study of the effect of bazedoxifene acetate on incident vertebral fractures in three different geographical regions.

Results

We made four observations: (1) bone mass density changes varied largely across participants, (2) baseline age and body mass index influenced baseline bone mass density that, in turn, had an effect on prevalent fractures, (3) direct and/or indirect effects of bazedoxifene acetate on incident fractures were different across regions, and (4) estimates of indirect effects were sensible to the presence of post-treatment unmeasured confounders. In one region, around 40% of the bazedoxifene acetate effect on the occurrence of fracture is explained by its effect on bone mass density. Under the counterfactual approach, these 40% represent the average difference in the occurrence of fracture observed for untreated individuals when their bone mass density values are set at the value under bazedoxifene acetate versus under placebo.

Conclusions

Computational methods are available to evaluate and interpret the surrogacytic capability of a biomarker of a primary outcome.

Keywords

Causal analysis structural equation model piecewise regression bone mineral density vertebral fracture bazedoxifene acetate

Get full access to this article

View all access options for this article.

References

Johnell

Kanis

. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726–1733.

Ho-Pham

Nguyen

. Prevalence and risk factors of radiographic vertebral fracture in postmenopausal Vietnamese women. Bone 2009; 45: 213–217.

van der Klift

de Laet

Pols

. Assessment of fracture risk: who should be treated for osteoporosis? Best Pract Res Clin Rheumatol 2005; 19: 937–950.

Ross

. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med 1996; 156: 1399–1411.

Bruyere

Roux

Detilleux

. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007; 92: 3076–3081.

Hartl

Tyndall

Kraenzlin

. Discriminatory ability of quantitative ultrasound parameters and bone mineral density in a population-based sample of postmenopausal women with vertebral fractures: results of the Basel Osteoporosis Study. J Bone Miner Res 2002; 17: 321–330.

Weinans

. Architectural changes independent of bone mineral in osteoporosis. J Musculoskelet Neuronal Interact 2002; 2: 535–537.

Wegrzyn

Roux

Arlot

. Role of trabecular microarchitecture and its heterogeneity parameters in the mechanical behavior of ex vivo human L3 vertebrae. J Bone Miner Res 2010; 25: 2324–2331.

FRAX® - Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX/. Accessed on February10, 2012.

10.

Small

. Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed 2005; 7: 3–3.

11.

Miller

Chines

Christiansen

. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008; 23: 525–535.

12.

Freedman

Graubard

Schatzkin

. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11: 167–178.

13.

Meredith

Hoseyni

. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 2001; 20: 3175–3188.

14.

Buyse

Molenberghs

Burzykowski

. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1: 49–67.

15.

Hafeman

. “Proportion explained”: a causal interpretation for standard measures of indirect effect? Am J Epidemiol 2009; 170: 1443–1448.

16.

Finkelstein

Brockwell

Mehta

. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008; 93: 861–868.

17.

Itabashi

Yoh

Chines

. Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J Bone Miner Res 2011; 26: 519–529.

18.

Cummings

Karpf

Harris

. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112: 281–289.

19.

Kupek

. Beyond logistic regression: structural equations modelling for binary variables and its application to investigating unobserved confounders. BMC Med Res Methodol 2006; 6: 13–13.

20.

Ditlevsen

Christensen

Lynch

. The mediation proportion: a structural equation approach for estimating the proportion of exposure effect on outcome explained by an intermediate variable. Epidemiology 2005; 16: 114–120.

21.

Case

. Quantifying the indirect treatment effect via surrogate markers. Stat Med 2006; 25: 223–231.

22.

Have

Joffe

Lynch

. Causal mediation analyses with rank preserving models. Biometrics 2007; 63: 926–934.

23.

Imai

Keele

Yamamoto

. Identification, inference and sensitivity analysis for causal mediation effects. Stat Sci 2010; 25: 51–71.

24.

VanderWeele

Vansteelandt

. Conceptual issues concerning mediation, interventions and composition. Stat Interface 2009; 2: 457–468.

25.

Petersen

Sinisi

van der Laan

. Estimation of direct causal effects. Epidemiology 2006; 17: 276–284.

26.

Silverman

Christiansen

Genant

. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008; 23: 1923–1934.

27.

Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17: 716-724.

28.

Clark

Cons-Molina

Deleze

. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 2009; 20: 275–282.

29.

Jacobs

Da Silva

Armbrecht

et al . Prediction of vertebral fractures is specific for gender and site of bone mineral density measurement. J Rheumatol 2010; 37: 149–154.

30.

Lunn

Thomas

Best

. WinBUGS a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000; 10: 325–337.

31.

Ahlborg

Johnell

Turner

. Bone loss and bone size after menopause. N Engl J Med 2003; 349: 327–334.

32.

Barrera

Bunout

Gattas

. A high body mass index protects against femoral neck osteoporosis in healthy elderly subjects. Nutrition 2004; 20: 769–771.

33.

Pirro

Fabbriciani

Leli

. High weight or body mass index increase the risk of vertebral fractures in postmenopausal osteoporotic women. J Bone Miner Metab 2010; 28: 88–93.

34.

Ferrar

Roux

Felsenberg

. Association between incident and baseline vertebral fractures in European women: vertebral fracture assessment in the Osteoporosis and Ultrasound Study (OPUS). Osteoporos Int 2012; 23: 59–65.

35.

Roux

Fechtenbaum

Kolta

. Mild prevalent and incident vertebral fractures are risk factors for new fractures. Osteoporos Int 2007; 18: 1617–1624.

36.

Berger

Goltzman

Langsetmo

. Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 2010; 25: 1948–1957.

37.

Langsetmo

Hanley

Prior

. Dietary patterns and incident low-trauma fractures in postmenopausal women and men aged >/= 50 y: a population-based cohort study. Am J Clin Nutr 2011; 93: 192–199.

38.

W-F

Hou

S-X

. Genetics of osteoporosis: perspectives for personalized medicine. Personal Med 2010; 7: 655–668.

39.

Marini

Brandi

. Pharmacogenetics of osteoporosis. F1000 Biol Rep. 2010; 2: 63–63.

40.

Ten have

Joffe

. A review of causal estimation of effects in mediation analyses. Stat Meth Med Res 2012; 21: 77–107.